Vital Therapies, Inc. (VTL) Downgraded by BidaskClub to “Hold”

Vital Therapies, Inc. (NASDAQ:VTL) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

A number of other brokerages also recently commented on VTL. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 21st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.00.

Vital Therapies (VTL) opened at $5.75 on Thursday. Vital Therapies has a 1 year low of $2.25 and a 1 year high of $6.50.

Vital Therapies (NASDAQ:VTL) last released its earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02. During the same period in the previous year, the company posted ($0.32) earnings per share. equities research analysts forecast that Vital Therapies will post -1.29 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2017/11/09/vital-therapies-inc-vtl-downgraded-by-bidaskclub-to-hold.html.

In other Vital Therapies news, Director Muneer A. Satter bought 130,000 shares of the business’s stock in a transaction on Thursday, September 14th. The stock was bought at an average price of $4.01 per share, with a total value of $521,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime bought 10,000 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were acquired at an average cost of $4.00 per share, with a total value of $40,000.00. Following the purchase, the director now owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 190,000 shares of company stock worth $737,800. 32.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of VTL. Bank of New York Mellon Corp increased its stake in Vital Therapies by 11.5% during the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after acquiring an additional 9,120 shares during the last quarter. FMR LLC increased its stake in Vital Therapies by 102.9% during the first quarter. FMR LLC now owns 2,957,878 shares of the company’s stock worth $11,832,000 after acquiring an additional 1,500,000 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after acquiring an additional 1,157 shares during the last quarter. LMR Partners LLP acquired a new stake in Vital Therapies during the second quarter worth $396,000. Finally, Blair William & Co. IL increased its stake in Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after acquiring an additional 40,000 shares during the last quarter. 25.63% of the stock is owned by institutional investors.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply